Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...

iPS Cell Differentiation

iPS Cell Differentiation

The ability of induced pluripotent stem cells or iPSCs to differentiate into most body cell types has stimulated repair and regenerative medicine research over the past few decades. iPSC-derived blood cells, hepatocytes, beta islet cells, cardiomyocytes, neurons, and other cell types can repair injuries or regenerate damaged tissue in diseases such as diabetes and neurodegenerative disorders.

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

Forced Transdifferentiation

Forced Transdifferentiation

Transdifferentiation, also known as lineage reprogramming, was first discovered by Selman and Kafatos in 1974 in silkmoths. They observed that the moths’ cuticle-producing cells transformed into salt-producing cells. Many such cases of natural transdifferentiation occur in organisms. In humans, pancreatic alpha cells can become beta cells. In newts, the loss of the eye’s lens causes the pigmented epithelial cells to transdifferentiate into the lens cells.
Artificial transdifferentiation occurs...

Differentiation of Common Myeloid Progenitor Cells

Differentiation of Common Myeloid Progenitor Cells

Common myeloid progenitors (CMPs) are oligopotent cells that can differentiate into granulocytes and macrophages. Granulocytes and macrophages are essential for protecting the body against bacterial, viral, or fungal infections. They migrate from the bone marrow into the circulating blood to reach specific tissue sites where they differentiate and help in immune surveillance. However, they survive only for a few days and must be continuously made available to the organism to maintain a robust...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Pathogenesis of diffuse large B cell lymphoma proteogenotypes.

Cancer cell·2026

Same author

SPEN loss drives extra-follicular diffuse large B cell lymphoma with female-specific lethality and therapeutic vulnerabilities.

Cancer discovery·2026

Same author

Enhanced efficacy of a specific HDAC3 inhibitor in combination with 5-azacitidine against diffuse large B-cell lymphoma.

Blood neoplasia·2026

Same author

Elevated levels of TNF and its targets characterize better-risk older acute myeloid leukemia patients.

Leukemia·2026

Same author

CCAAT-enhancer binding protein delta functions as a tumor suppressor gene in acute myeloid leukemia.

Neoplasia (New York, N.Y.)·2026

Same author

The LMO2-LDB1-TAL1 complex regulates transcription networks in acute myeloid leukemia.

Blood neoplasia·2026

Search research articles

Related Experiment Video

Updated: May 10, 2026

A Protocol for Explant Cultures of IDH1-mutant Diffuse Low-grade Gliomas

A Protocol for Explant Cultures of IDH1-mutant Diffuse Low-grade Gliomas

Published on: May 9, 2025

Differentiation therapy for IDH1/2 mutant malignancies.

Francine E Garrett-Bakelman¹, Ari M Melnick

¹Department of Medicine, Division of Hematology/Oncology, Weill Cornell Medical College, 1300 York Ave, New York, NY 10065, USA.

|June 5, 2013

Summary

New inhibitors targeting isocitrate dehydrogenase (IDH1 and IDH2) mutations show promise. These small molecules combat cancer by inducing differentiation in myeloid leukemias and malignant gliomas.

More Related Videos

A Protocol for Rapid Post-mortem Cell Culture of Diffuse Intrinsic Pontine Glioma (DIPG)

A Protocol for Rapid Post-mortem Cell Culture of Diffuse Intrinsic Pontine Glioma (DIPG)

Published on: March 7, 2017

Flow Cytometry-based Drug Screening System for the Identification of Small Molecules That Promote Cellular Differentiation of Glioblastoma Stem Cells

Flow Cytometry-based Drug Screening System for the Identification of Small Molecules That Promote Cellular Differentiation of Glioblastoma Stem Cells

Published on: January 10, 2018

Related Experiment Videos

Last Updated: May 10, 2026

A Protocol for Explant Cultures of IDH1-mutant Diffuse Low-grade Gliomas

A Protocol for Explant Cultures of IDH1-mutant Diffuse Low-grade Gliomas

Published on: May 9, 2025

A Protocol for Rapid Post-mortem Cell Culture of Diffuse Intrinsic Pontine Glioma (DIPG)

A Protocol for Rapid Post-mortem Cell Culture of Diffuse Intrinsic Pontine Glioma (DIPG)

Published on: March 7, 2017

Flow Cytometry-based Drug Screening System for the Identification of Small Molecules That Promote Cellular Differentiation of Glioblastoma Stem Cells

Flow Cytometry-based Drug Screening System for the Identification of Small Molecules That Promote Cellular Differentiation of Glioblastoma Stem Cells

Published on: January 10, 2018

Area of Science:

Biochemistry
Oncology
Molecular Biology

Background:

Recurrent somatic mutations in metabolic enzymes IDH1 and IDH2 are linked to cancer.
These mutations lead to the production of the oncometabolite 2-hydroxyglutarate (2-HG).
Aberrant 2-HG contributes to malignant transformation in hematopoietic and glial cells.

Purpose of the Study:

To describe the development of novel small-molecule inhibitors targeting IDH1 and IDH2 mutations.
To evaluate the efficacy of these inhibitors in inducing cell differentiation.

Main Methods:

Development of mutant-specific small-molecule inhibitors for IDH1 and IDH2.
Testing inhibitor effects on cell differentiation in relevant cancer models.

Main Results:

The first IDH1 and IDH2 mutant-specific small-molecule inhibitors were reported.
These inhibitors demonstrated the ability to induce cell differentiation.
Therapeutic potential observed in myeloid leukemias and malignant gliomas.

Conclusions:

Targeting IDH1/IDH2 mutations with specific inhibitors is a viable therapeutic strategy.
Induction of cell differentiation offers a new approach to treating IDH-mutant cancers.
Small-molecule inhibitors represent a promising avenue for IDH-mutant leukemia and glioma treatment.